Share this article on:

The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study

Cooper, Vanessa PhD*; Horne, Rob PhD*; Gellaitry, Grace BA (Hons)*; Vrijens, Bernard PhD†‡; Lange, Anne-Catherine MSc†; Fisher, Martin MBBS§; White, David MBBS‖

JAIDS Journal of Acquired Immune Deficiency Syndromes: 1 March 2010 - Volume 53 - Issue 3 - pp 369-377
doi: 10.1097/QAI.0b013e3181ccb762
Epidemiology and Social Science

Objective: To determine the impact of once-nightly versus twice-daily dosing and beliefs about highly active antiretroviral therapy (HAART) on adherence to efavirenz-based HAART in antiretroviral-naive patients.

Methods: A multicenter, open-label, 48-week, randomized controlled trial. Participants were randomized to receive once nightly didanosine plus lamivudine, or twice-daily combivir (zidovudine plus lamivudine) both in combination with efavirenz. Medication Event Monitoring Systems were used to compile drug-dosing histories. Beliefs about HAART (necessity and concerns) were measured at baseline using validated questionnaires. Perceptions of HAART intrusiveness were assessed after 4 weeks.

Results: Eighty-seven patients were randomized (44 once-nightly and 43 twice-daily). Overall adherence was higher among the once-nightly arm (P = 0.0327). Eighty-one percent once-nightly and 62% twice-daily patients persisted with treatment for 48 weeks (P = 0.0559). Regimen execution was similar between both arms. Participants were significantly less likely to persist with HAART if their initial concerns about HAART were high relative to their perceived need for treatment (P = 0.025).

Conclusions: The difference in adherence observed between once-nightly and twice-daily dosing was driven by a difference in persistence with treatment. Psychological preparation for starting HAART should address patients' perceptions of necessity for HAART and concerns about adverse effects to maximize persistence with treatment.

From the *Department of Practice and Policy, Center for Behavioural Medicine, The School of Pharmacy, University of London, London, United Kingdom; †Pharmionic Research Centre, Visé, Belgium; ‡University of Liege, Liege, Belgium; §Department of HIV/GUM, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; and ‖Department of Sexual Health and HIV, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.

Received for publication September 30, 2008; accepted May 6, 2009.

Sponsored by an educational grant from Bristol-Myers Squibb.

Presented at the 8th International Congress on Drug Therapy in HIV Infection, November 12-16, 2006, Glasgow, United Kingdom.

Correspondence to: Dr. Vanessa Cooper, PhD, Department of Practice and Policy, Center for Behavioural Medicine, The School of Pharmacy, University of London, Mezzanine Floor, BMA House, Tavistock Square, London WC1H 9JP, United Kingdom (e-mail: vanessa.cooper@pharmacy.ac.uk).

© 2010 Lippincott Williams & Wilkins, Inc.